Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
News18 » Business
1-min read

Wockhardt Shares Climb 14% after Getting Approval for Two New Antibiotics

In a filing to stock exchanges, Wockhardt said that it has received approval from the Drugs Controller General of India (DCGI) for its two new antibiotics -- Emrok (intravenous infusion) and EMROK O (Oral) – to treat skin and other drug-resistant infections.

Trending Desk

Updated:January 16, 2020, 3:48 PM IST
facebookTwitter Pocket whatsapp
Wockhardt Shares Climb 14% after Getting Approval for Two New Antibiotics
Representative image.

New Delhi: Wockhardt Ltd shares surged as much as 14% in intra-day trade on Thursday, i.e. 16 January, after the pharmaceutical company received regulatory approval for two new antibiotics in India.

At 2:36pm, shares of Wockhardt were trading at Rs 277.55, up 7%, after hitting the day’s high of Rs 295.70. The stock has lost a whopping 45% in the past one year compared with a nearly 14% rise in the benchmark Nifty 50 index.

In a filing to stock exchanges, Wockhardt said that it has received approval from the Drugs Controller General of India (DCGI) for its two new antibiotics -- Emrok (intravenous infusion) and EMROK O (Oral) – to treat skin and other drug-resistant infections, including diabetic foot infections and concurrent bacteraemia.

“Wockhardt becomes the first domestic drug maker to get approval for novel antibiotic drugs discovered, developed and manufactured in India,” managing director Murtaza Khorakiwala said during a conference call, adding that the two drugs will be launched in the next few months in India and later in China and other emerging markets.

The new drug will target superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR).

“By virtue of its broad spectrum activity against widely prevalent pathogens, including MRSA, superior safety over the currently available anti-MRSA agents and its unique properties, I believe EMROK/EMROK-O has a strong potential to effectively address the unmet medical need of the clinicians in the country,” said Dr Habil Khorakiwala, founder-chairman of Wockhardt Group.

Highlighting the scope of the new drugs, the company said that the size of the Indian antibiotic market is currently around Rs 16,000 crore. Growing at 7%, it is one of the largest therapeutic segments, with a 12% market share of the Indian pharmaceutical market, it added.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Read full article
Next Story
Next Story

facebookTwitter Pocket whatsapp
Most Active
Company Price Change %Gain
Reliance 1,532.00 -3.08
Bharti Airtel 509.25 1.85
TCS 2,170.25 -2.16
Kotak Mahindra 1,618.05 -4.70
HDFC Bank 1,254.90 -1.80
Top Gainers
Company Price Change %Gain
Power Grid Corp 204.80 3.75
Bharti Airtel 509.25 1.85
Asian Paints 1,846.20 0.82
ITC 241.90 0.85
ICICI Bank 534.85 0.74
Top Losers
Company Price Change %Gain
Kotak Mahindra 1,618.05 -4.70
Reliance 1,532.00 -3.08
ONGC 122.35 -2.39
TCS 2,170.25 -2.16
NTPC 118.70 -2.06

Live TV

Countdown To Elections Results
To Assembly Elections 2018 Results